Effects on 17β-estradiol and phytoestrogen α-zearalanol on tissue factor in plasma of ovariectomized rats and HUVECs

Chinese Journal of Physiology

Volumn 47, Issue 2, 2004, Pages 67-72

  Wang, Wen ^a   Zhu, Guang Jin ^a   Zu, Shu Yu ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

17 estradiol; HUVECs; Ovariectomized rats; Tissue factor; zearalanol

Indexed keywords

ESTRADIOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NUCLEAR PROTEIN; PHYTOESTROGEN; THROMBOPLASTIN; TRANSCRIPTION FACTOR AP 1; ZERANOL; ESTROGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; EXTRACTION; FEMALE; HEART DISEASE; HEART PROTECTION; HUMAN; HUMAN CELL; INCUBATION TIME; NONHUMAN; OVARIECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; UMBILICAL VEIN; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL LINE; DRUG EFFECT; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BLOTTING, WESTERN; CELL LINE; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; ESTROGENS, NON-STEROIDAL; FEMALE; HUMANS; NF-KAPPA B; OVARIECTOMY; PHYTOESTROGENS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THROMBOPLASTIN; TRANSCRIPTION FACTOR AP-1; ZERANOL;

EID: 3042847507     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Aune, B., Oian, P., Omsjo, I. and Osterud, B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood-A beneficial effect on atherogenesis and thrombus formation? Am. J. Obstet. Gynecol. 173: 1816-1820, 1995.
2. Chae, C.U., Ridker, P.M. and Manson, J.E. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb. Haemost.78: 770-780, 1997.
3. Chiu, J.J., Lee, P.L., Lee, C.I.,Chen, L.J., Chen, C.N., Ko, Y.C. and Lien, S.C. Shear stress attenuates tumor necrosis factor-α-induced monocyte chemotactic protein-1 expressions in endothelial cells. Chinese J. Physiol. 45: 169-176, 2002.
4. Dai, S.L., Duan, J., Lu, Y., Cheng, J., Ren, J., Zhang, Y. Zhao, X., Zhang, L., Wu, Y. and Ge, Q.A new phytoestrogen α -zearalanol markedly inhibits progression of atherogensis in overiectomized cholesterol-fed rabbits(Abstract A01). The 24th Annual scientific sessions, North American section of the international society for heart research, Madison, USA, 2002, p. 3.
5. Falciani, M., Gori, A.M., Fedi, S., Chiarugi, L., Simonetti, I., Dabizzi, R.P., Prisco, D., Pepe, G., Abbate, R., Gensini, G.F. and Neri Serneri, G.G. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb. Haemost. 79: 495-499, 1998.
6. Gao, Y.M. and Zhu, G.J. Effects of tumor necrosis factor α and angiotensin II on expression of tissue factor in human vascular endothelial cells. Basic Med. Clin. 20: 126-129, 2000.
7. Grimes, D.A. and Lobo, R.A. Perspectives on the women's health initiative trial of hormone replacement therapy. Obstet. Gynecol. 100: 1344-1353, 2002.
8. Holschermann, H., Terhalle, H.M., Zakel, U., Maus, U., Parviz, B., Tillmanns, H. and Haberbosch, W. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives. Thromb. Haemost. 82: 1614-1620, 1999.
9. Iochmann, S., Reverdian-Moalic, P., Beaujean, S., Rideau, E., Lebranchu, Y., Bardos, P. and Gruel, Y. Fast dection of tissue factor and tissue factor pathway inhibitor messenger RNA in endothelial cells and monocytes by sensitive reverse transcription-polymerase chain reaction. Thromb. Res. 94: 165-173, 1999.
10. Ishii, H., Takada, K., Higuchi, T. and Sugiyama, J. Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-kappaB/Rel and AP-1. Thromb. Haemost. 84: 712-721, 2000.
11. Jaffe, E.A., Nachman, R.L., Becker, C.G.and Minick, C.R.Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52: 2745-2756, 1973.
12. Koh, K.K. Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women. Int. J. Hematol.76 Suppl 2: 44-46, 2002.
13. Koh, K.K., Kang, M.H., Jin, D.K., Lee, S.K., Ahn, J.Y., Hwang, H.Y., Yang, S.H., Kim, D.S., Ahn, T.H. and Shin, E.K. Vascular effects of estrogen in type II diabetic postmenopausal women. J. Am. Coll. Cardiol. 38: 1409-1415, 2001.
14. Lobo, R.A. Benefits and risks of estrogen replacement therapy. Am. J. Obstet. Gynecol. 173: 982-990, 1995.
15. Mackman, N. Regulation of the tissue factor gene. Thromb. Haemost. 78: 747-754, 1997.
16. Mammen, E.F. Oral contraceptive pills and hormonal replacement therapy and thromboembolic disease. Hematol. Oncol. Clin. North Am. 14: 1045-1059, 2000.
17. Martin, D.M., Wiiger, M.T. and Prydz, H. Tissue factor and biotechnology. Thromb. Res. 90: 1-25, 1998.
18. Rauch, U. and Nemerson, Y. Circulating tissue factor and thrombosis. Curr. Opin. Hematol. 7: 273-277, 2000.
19. Reid, R.L. Progestins in hormone replacement therapy: Impact on endometrial and breast cancer. J. SOGO. 22: 677-681, 2000.
20. Rosano, G.M., Sarrel, P.M., Poole-Wilson, P.A. and Collins, P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 342: 133-136, 1993.
21. Simoncini, T., Maffei, S., Basta, G., Barsacchi, G., Genazzani, A.R., Liao, J.K., and Caterina, R. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ. Res. 87: 19-25, 2000.
22. Stampfer, M.J. and Coldity, G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prevent. Med. 20: 47-63, 1991.
23. Young R.L., Goepfert, A.R. and Goldzieher, H.W. Estrogen replacement therapy is not conducive of venous thromboembolism. Maturitas 13: 189-192, 1991.